Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlaxoSmithKline
A Multi-Centre, Multi-country, Randomized, Double-Blind (Subject, Investigator), Placebo-Controlled, Repeat-Dose study to evaluate the Efficacy and Safety of Intravenous GSK679586 in Patients with Severe Asthma
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
history of asthma for ≥ 6 months
taking inhaled corticosteroids
non-smoking
Baseline (pre-bronchodilator) FEV1 35-80% predicted at screening.
Reversible airways disease as indicated by an increase of FEV1 ≥12% from baseline after nebulised salbutamol or albuterol.
symptomatic according to the ACQ-7
You may not be if
Unstable severe asthma
Recent respiratory illness
Presence of other respiratory disease or chronic pulmonary condition other than asthma
Treatment with omalizumab within 4 months of study
Recent gastrointestinal or respiratory parasitic infestation
History of severe allergy to food or drugs
Clareo Health | Efficacy and Safety Study of GSK679586 in Patients With Severe Asthma
